Clinical data examining the association of PD-L1 expression and EGFR and KRAS biomarkers with survival in NSCLC may help elucidate the interplay between these biomarkers and any potential effect on patient prognosis. This evidence concerns the gene KRAS and non-small cell lung carcinoma.